Canada's health regulator has approved a gene therapy for the treatment of haemophilia B, a genetic blood disorder.
Pfizer's drug, Beqvez, follows the approval of CSL's drug, Hemgenix, which was approved in Canada in October 2023.
The US Food and Drug Administration (FDA) is expected to give its decision on Beqvez in the second quarter of 2024. Hemgenix was approved by the FDA in November 2022 (see BioNews 1169).
For more information read CBC News.
Related Articles
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
NHS funding approved for haemophilia B gene therapy
A new gene therapy for haemophilia B is to be made available for NHS patients after approval from the UK's National Institute for Health and Care Excellence.
